Key result
Commentary evaluates admission lactate levels in STEMI-CS patients treated with Impella.
Key points are not available for this paper at this time.
Answers are grounded in this paper and cite their sources.
Admission lactate may inform risk stratification in Impella-treated STEMI shock; leaves open prospective validation of thresholds.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Hayat et al. (2025) studied this question. Admission lactate levels in STEMI patients with cardiogenic shock treated with Impella are evaluated in this commentary based on previously published literature.
Synapse has enriched 10 related papers. Consider them for comparative context: